Related Experiment Video

Updated: Jun 22, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis

Qing-He Nie1, Chuan-Long Zhu, Ya-Fei Zhang

  • 1Chinese PLA Centre of Diagnosis and Treatment for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xinsi Road, 710038 Xi'an, Shaanxi Province, People's Republic of China. nieqinghe@163.com

Digestive Diseases and Sciences
|June 12, 2009
PubMed
Abstract

Insights

Targeting TIMP-2 with antisense oligonucleotides (ASONS) effectively reduced liver fibrosis in a rat model. This genetic approach shows promise for developing new anti-fibrosis therapies by inhibiting TIMP-2 expression and collagen deposition.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Drug Discovery

Background:

  • Liver fibrosis, often caused by HBV and HCV, involves TIMP-1 and TIMP-2.
  • TIMP-1 inhibition via antisense oligonucleotides (ASONS) shows antifibrotic effects.
  • The role of TIMP-2 in liver fibrosis progression remained unclear.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting TIMP-2 in liver fibrosis.
  • To determine if blocking TIMP-2 expression with ASONs can prevent liver fibrosis progression.

Main Methods:

  • Designed and synthesized two TIMP-2 targeting ASONs.
  • Administered ASONs via hydrodynamic injection into rat livers with induced fibrosis.
  • Validated TIMP-2 knockdown and assessed downstream effects on fibrotic markers in vitro and in vivo.

Main Results:

  • TIMP-2 ASON significantly reduced TIMP-2 expression.
  • TIMP-2 ASON treatment decreased collagen I and IV deposition.
  • Ameliorated liver pathology and improved liver function in the fibrosis model.

Conclusions:

  • TIMP-2 ASON demonstrates efficacy in preventing liver fibrosis progression in a rat model.
  • This study supports TIMP-2 as a viable genetic target for antifibrotic therapies.
  • Suggests potential for developing novel genetic-level anti-fibrosis drugs.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...